Causes of death since the first treatment for progression in the TL-post-CAR-T set
| . | TL-post-CAR-T set . | Period of first progression ≤6 mo . | Period of first progression >6 mo . | |||
|---|---|---|---|---|---|---|
| N = 52 . | n = 42 . | n = 10 . | ||||
| Event according to OS definition since first treatment for progression | ||||||
| No | 17 | (32.7%) | 8 | (19.0%) | 9 | (90.0%) |
| Yes | 35 | (67.3%) | 34 | (81.0%) | 1 | (10.0%) |
| If yes, cause of death | ||||||
| Progression | 32 | (91.4%) | 31 | (91.2%) | 1 | (100.0%) |
| Concurrent illness | 2 | (5.7%) | 2 | (5.9%) | 0 | (0.0%) |
| Late toxicity | 1 | (2.9%) | 1 | (2.9%) | 0 | (0.0%) |
| . | TL-post-CAR-T set . | Period of first progression ≤6 mo . | Period of first progression >6 mo . | |||
|---|---|---|---|---|---|---|
| N = 52 . | n = 42 . | n = 10 . | ||||
| Event according to OS definition since first treatment for progression | ||||||
| No | 17 | (32.7%) | 8 | (19.0%) | 9 | (90.0%) |
| Yes | 35 | (67.3%) | 34 | (81.0%) | 1 | (10.0%) |
| If yes, cause of death | ||||||
| Progression | 32 | (91.4%) | 31 | (91.2%) | 1 | (100.0%) |
| Concurrent illness | 2 | (5.7%) | 2 | (5.9%) | 0 | (0.0%) |
| Late toxicity | 1 | (2.9%) | 1 | (2.9%) | 0 | (0.0%) |